AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29308939
Drug: Kinesio Taping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinesio Taping (standard treatment plus application of Kinesio Taping on the respiratory muscles)
Trial: 24965569
Drug: Rilotumumab 15
RxNorm normalized name: Rilotumumab
DrugBank: Rilotumumab (DB11972)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilotumumab 15 mg/kg plus ECX
Trial: 24965569
Drug: Rilotumumab 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilotumumab 7.5 mg/kg plus ECX
Trial: 24965569
Drug: Combined rilotumumab
RxNorm normalized name: Rilotumumab
DrugBank: Rilotumumab (DB11972)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined rilotumumab (both doses) plus ECX
Trial: 20171420
Drug: NXN-188 (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NXN-188 (doses of 2 to 800 mg, 0.027-11.2 mg/kg)
Trial: 15132403
Drug: Ezetimibe coadministered
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe coadministered with simvastatin (10 mg ezetimibe + simvastatin at 10, 20, 40, or 80 mg/d)
Trial: 15132403
Drug: Ezetimibe coadministered
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe coadministered with simvastatin (10 mg ezetimibe + simvastatin at 10 mg/d)
Trial: 15132403
Drug: Ezetimibe/simvastatin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe/simvastatin and simvastatin monotherapy
Trial: 3723999
Drug: 1 dose
RxNorm normalized name: Ribose 3 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of 0.1 ml human diploid cell vaccine (HDCV)
Trial: 3723999
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of 0.1 ml human diploid cell vaccine (HDCV)
Trial: 3723999
Drug: 4 doses
RxNorm normalized name: parathyroid hormone 25 MCG/Dose Cartridge, 14 Doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 doses of 0.1 ml human diploid cell vaccine (HDCV)
Trial: 3723999
Drug: 8 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 doses of 0.1 ml human diploid cell vaccine (HDCV)
Trial: 30322724
Drug: Single-course clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-course clindamycin (300 mg twice-daily for 4 days)
Trial: 30322724
Drug: Triple-course clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-course clindamycin (300 mg twice-daily for 4 days)
Trial: 27385272
Drug: Sleep education
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sleep education program with self-help treatment
Trial: 3055791
Drug: Bupivacaine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (2 mg/kg)
Trial: 18188762
Drug: Nicotine vaccine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine vaccine (100 microg of purified 3'-aminomethylnicotine conjugated to detoxified Pseudomonas aeruginosa r-exoprotein A)
Trial: 18188762
Drug: Nicotine vaccine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine vaccine (fourth dose at day 182)
Trial: 15879167
Drug: Oral Contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Contraceptive (OC) users during luteal phase (Lut)
Trial: 15879167
Drug: Nonusers of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonusers of Oral Contraceptives (NOC)
Trial: 15879167
Drug: Oral Contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Contraceptive (OC) users during follicular phase (Fol)
Trial: 7540996
Drug: Escalating dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating dosage of interferon alfa (starting at 3 million units, increasing to 5 million units at 8 weeks for nonresponders, and to 10 million units 8 weeks later for persistent nonresponders)
Trial: 7540996
Drug: Constant dosage
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constant dosage of interferon alfa (3 million units three times weekly for 24 weeks)
Trial: 2212144
Drug: Topical formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical formulation A of 2.5% hydrocortisone cream
Trial: 2212144
Drug: Topical formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical formulation B of 2.5% hydrocortisone cream
Trial: 648169
Drug: Griseofulvin every
RxNorm normalized name: Griseofulvin
DrugBank: Griseofulvin (DB00400)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Griseofulvin every other day (5 mg/lb, max 1 gm/day)
Trial: 648169
Drug: Griseofulvin twice
RxNorm normalized name: Griseofulvin
DrugBank: Griseofulvin (DB00400)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Griseofulvin twice a week (5 mg/lb, max 1 gm/day)
Trial: 30850011
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg tamoxifen
Trial: 30850011
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg tamoxifen
Trial: 31940324
Drug: Anti-viral treatment
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-viral treatment
Trial: 20391505
Drug: Experimental knee
RxNorm normalized name: Bos taurus knee joint preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental knee pain (hypertonic saline injections 0.75 ml)
Trial: 10601914
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy (1 mg micronized 17beta‐estradiol daily sequentially combined with 5 or 10 mg dydrogesterone for 14 days of each 28‐day cycle during 12 months and 2 mg 17beta‐estradiol combined with 10 mg dydrogesterone thereafter for a period of 3 months)
Trial: 2245833
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC) and intrauterine insemination (IUI)
Trial: 7449382
Drug: TGLVP (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TGLVP (0.5 mg and 1 mg)
Trial: 7449382
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no drug injection)
Trial: 6466531
Drug: Suxamethonium 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suxamethonium 10 mg pretreatment followed by 1 mg/kg suxamethonium
Trial: 31714912
Drug: Testosterone (Tostran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone (Tostran 2% gel)
Trial: 29183257
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (0.2 g.kg-1 BM)
Trial: 29183257
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (0.3 g.kg-1 BM)
Trial: 29183257
Drug: Placebo (0.07
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.07 g.kg-1 BM sodium chloride)
Trial: 22378800
Drug: Probiotic preparation,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic preparation, specific dosage and duration not mentioned
Trial: 17584828
Drug: Mifepristone (RU486),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (RU486), single dose administered during the mid-secretory phase.
Trial: 10449105
Drug: anti-alpha4 integrin
RxNorm normalized name: Anti-alpha4 integrin
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: anti-alpha4 integrin antibody (natalizumab; Antegren)
Trial: 7840362
Drug: 4 mg/day
RxNorm normalized name: Neupro 4 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/day of oral dexamethasone for 4 days
Trial: 525066
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg piroxicam daily for two weeks (7 patients)
Trial: 525066
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg indomethacin tid for two weeks (9 patients)
Trial: 525066
Drug: Side effects
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Side effects due to trial treatment
Trial: 25601604
Drug: Caffeine 100
RxNorm normalized name: caffeine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 100 mg encapsulated, taken 2 hours prior to intercourse for 3 weeks
Trial: 24503140
Drug: Pitavastatin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitavastatin (4 mg) plus Eicosapentaenoic acid (EPA) (1800 mg)
Trial: 17478464
Drug: Lumiracoxib 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumiracoxib 400 mg once daily (o.d.)
Trial: 17478464
Drug: Indomethacin 50
RxNorm normalized name: indomethacin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 50 mg three times daily (t.i.d.)
Trial: 8638525
Drug: Intermittent administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent administration of organic nitrates
Trial: 8233745
Drug: DTP-HbOC combined
RxNorm normalized name: DTP-348
DrugBank: DTP-348 (DB12741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTP-HbOC combined vaccine (0.5 mL injection)
Trial: 8233745
Drug: Separate administration
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate administration of DTP and HbOC (0.5 mL each in separate legs)
Trial: 2992116
Drug: Suloctidil (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suloctidil (200 mg t.i.d.)
Trial: 29231546
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy group with acupuncture and huazhuo jiedu jiangni decoction
Trial: 29231546
Drug: Western medication
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medication group with omeprazole (20 mg, twice a day)
Trial: 29231546
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal medicine group (decoction only)
Trial: 26243048
Drug: Targeted percutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted percutaneous microwave ablation combined with mediastinal radiotherapy with or without chemotherapy (ablation group)
Trial: 26243048
Drug: Radiotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy with or without chemotherapy (RT group)
Trial: 23390005
Drug: Coping Cat
RxNorm normalized name: cat hair extract
DrugBank: Felis catus hair (DB10499)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coping Cat individual cognitive‐behavioral therapy (CBT)
Trial: 23390005
Drug: Medication management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication management with sertraline (SRT)
Trial: 23390005
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CBT and medication management
Trial: 23390005
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment conditions (CBT, SRT, COMB, PBO)
Trial: 21228609
Drug: Mirtazapine 30
RxNorm normalized name: mirtazapine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine 30 mg/day
Trial: 18854204
Drug: 1,25(OH)2D3 analog
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,25(OH)2D3 analog BXL746 (acute administration)
Trial: 18854204
Drug: Chronic administration
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic administration of BXL746
Trial: 18854204
Drug: 1,25(OH)2D3 (chronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,25(OH)2D3 (chronic administration)
Trial: 17135584
Drug: Diet plus
RxNorm normalized name: Glucomannan/Grapefruit Extract/Pyridoxine Oral Tablet [GRAPEFRUIT DIET PLUS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet plus pioglitazone (45 mg daily)
Trial: 17132769
Drug: No daily
RxNorm normalized name: Aveeno Daily Moisturizing
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No daily sunscreen use
Trial: 8180301
Drug: Daily NSAID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily NSAID usage
Trial: 28925324
Drug: Multi-layer compression
RxNorm normalized name: bandages, multi-layer compression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-layer compression therapy (MLCT)
Trial: 28925324
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with Cool Pack (CG)
Trial: 23288353
Drug: Mean arterial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mean arterial pressure (MAP) target of 80-85 mm Hg for 30 min (using norepinephrine infusion)
Trial: 20709569
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (midazolam and opioids)
Trial: 19579987
Drug: Metoprolol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (1 mg kg(‐1) daily)
Trial: 14963657
Drug: Oral corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral corticosteroids (initial dosages of 60-100 mg for 7-14 days, followed by dose reduction over several months)
Trial: 14963657
Drug: Intravenous corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous corticosteroids (initial dosages of 500-1,000 mg methylprednisolone at distinct intervals)
Trial: 11844203
Drug: Vaginal misoprostol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal misoprostol, 50 microg 6‐hourly
Trial: 11844203
Drug: Dinoprostone gel,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dinoprostone gel, 1‐2 mg 6‐hourly
Trial: 319204
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg naloxone i.v.
Trial: 30414387
Drug: Ticagrelor 180
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor 180 mg followed by 90 mg twice daily (ONSET/OFFSET study)
Trial: 30414387
Drug: Ticagrelor 60
RxNorm normalized name: ticagrelor 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor 60 mg twice daily (PEGASUS-TIMI 54 substudy)
Trial: 30414387
Drug: Ticagrelor 90
RxNorm normalized name: ticagrelor 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor 90 mg twice daily (PEGASUS-TIMI 54 substudy)
Trial: 30414387
Drug: Clopidogrel 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 600 mg followed by 75 mg once daily (ONSET/OFFSET study)
Trial: 16755160
Drug: Folate supplementation
RxNorm normalized name: folate
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folate supplementation (5 mg oral daily or 5 mg every other day)
Trial: 9055717
Drug: Community thrombolysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community thrombolysis (intravenous anistreplase administered by general practitioners)
Trial: 9055717
Drug: Hospital thrombolysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospital thrombolysis (intravenous anistreplase administered by secondary care clinicians)
Trial: 30621479
Drug: 1 L
RxNorm normalized name: BLUE 1 LAKE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 L polyethylene glycol with ascorbic acid plus 2 mg prucalopride (1LP/AP)
Trial: 30621479
Drug: 2 L
RxNorm normalized name: H-2 locus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 L polyethylene glycol with ascorbic acid (2LP/A)
Trial: 22843897
Drug: Gentle strength
RxNorm normalized name: Ex-Lax Gentle Strength
DrugBank: Sennosides (DB11365)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gentle strength training (lifting standardized weights weekly at 50% of h1RM)
Trial: 21092037
Drug: Transfusion therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfusion therapy after cardiopulmonary bypass with fibrinogen administration combined with traditional transfusion, guided by TEG (Group F)
Trial: 12750062
Drug: NG‐monomethyl‐L‐arginine (L‐NMMA;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NG‐monomethyl‐L‐arginine (L‐NMMA; 3 mg/kg over 5 min)
Trial: 12750062
Drug: NG‐monomethyl‐L‐arginine (L‐NMMA;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NG‐monomethyl‐L‐arginine (L‐NMMA; 6 mg/kg over 5 min)
Trial: 12750062
Drug: NG‐monomethyl‐L‐arginine (L‐NMMA;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NG‐monomethyl‐L‐arginine (L‐NMMA; 3 mg/kg and 6 mg/kg)
Trial: 1642662
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg oral tiludronate
Trial: 1642662
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg oral tiludronate
Trial: 1642662
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg oral tiludronate
Trial: 1642662
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg oral tiludronate
Trial: 31403974
Drug: Dexmedetomidine (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (low infusion rate: 0.5 μg · kg · h; moderate infusion rate: 1.5 μg · kg · h)
Trial: 31403974
Drug: Propofol (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (low infusion rate: 42 μg · kg · min; moderate infusion rate: 83 μg · kg · min)
Trial: 31403974
Drug: Dexmedetomidine (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (low infusion rate)
Trial: 31403974
Drug: Propofol (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (low infusion rate)
Trial: 31403974
Drug: Dexmedetomidine (moderate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (moderate infusion rate)
Trial: 31403974
Drug: Propofol (moderate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (moderate infusion rate)
Trial: 31403974
Drug: Dexmedetomidine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine and Propofol (both infusion rates)
Trial: 10804490
Drug: Suture closure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suture closure of the subcutaneous tissue
Trial: 24738117
Drug: Non-closure of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-closure of the subcutaneous tissue
Trial: 21236699
Drug: Lipid-lowering medications
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-lowering medications (LLMs) including statins
Trial: 7945126
Drug: cinnarizine 50
RxNorm normalized name: cinnarizine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cinnarizine 50 mg
Trial: 7945126
Drug: cinnarizine 25
RxNorm normalized name: cinnarizine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cinnarizine 25 mg
Trial: 2855116
Drug: Alcohol (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (1.2 g/kg)
Trial: 2855116
Drug: Alcohol (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0 g/kg)
Trial: 31788849
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg rectal diclofenac administered 30 minutes before ERCP
Trial: 25953193
Drug: Probiotic supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic supplements (Lactobacillus reuteri)
Trial: 25953193
Drug: Placebo (topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (topical oil application and lozenges)
Trial: 24756186
Drug: Melatonin (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (6 mg oral)
Trial: 8859725
Drug: THERATOPE STn‐KLH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THERATOPE STn‐KLH cancer vaccine emulsified in DETOX adjuvant
Trial: 8859725
Drug: Low‐dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low‐dose intravenous cyclophosphamide before ASI
Trial: 8859725
Drug: Anti‐KLH antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti‐KLH antibody titers
Trial: 1516489
Drug: Intermittent glyburide
RxNorm normalized name: Glyburide
DrugBank: Glyburide (DB01016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent glyburide therapy (2 weeks on, 2 weeks off)
Trial: 1516489
Drug: Continuous glyburide
RxNorm normalized name: Glyburide
DrugBank: Glyburide (DB01016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous glyburide therapy
Trial: 26540163
Drug: Telemedicine intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telemedicine intervention combining telemonitoring, medication management, self-management support, and depression management.
Trial: 24910934
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin A (BTA; onabotulinumtoxinA) injections; Female participants received 29 units; Male participants received 39 units
Trial: 24910934
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin A (BTA; onabotulinumtoxinA) injections
Trial: 20368402
Drug: Amodiaquine (AQ)
RxNorm normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amodiaquine (AQ) and Artesunate (AS) combination therapy